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Background and aim: A high D-dimer level may indicate the risk of coagulopathy and mortality in COVID-19 patients.
Thromboelastography (TEG) is a test that evaluates clot formation and fibrinolysis in real-time, unlike routine coagulation tests. The
study aimed to investigate the coagulation process with TEG in patients diagnosed with COVID-19.
Materials and Methods: The study was performed at our university hospital, chest diseases outpatient clinic as a cross-section study.
A total of 51 patients with 23 high D-dimer levels group (HDG) and 28 low D-dimers group (LDG) were included in the study. TEG
analysis was performed at the pretreatment evaluation in these two groups.
Results: D-dimer and fibrinogen levels of the HDG were higher than those of the LDG (550 vs. 90 ng/mL, p < 0.001; 521 vs. 269 mg/
dL, p < 0.001, respectively). In TEG analysis, HDG’s R and K values were lower than LDG, and HDG’s Angle, MA, and CI values were
higher than LDG (p = 0.037; p < 0.001; p < 0.001; p < 0.001; p < 0.001, respectively). ROC curve analysis suggested that the optimum
TEG parameters cut-off points for thrombosis risk were as below: for K was ≤2.1 min, for R was ≤6.1 min, for Angle was >62°, MA was
60.4 mm.
Conclusion: Our study showed that the risk of thrombosis might increase in COVID-19 patients who are not hospitalized in the
intensive care unit. Thrombosis risk should be investigated with TEG analysis and laboratory tests in every patient diagnosed with
COVID-19, and treatment should be started for risky patients.
Keywords: Thromboelastography, COVID-19, D-Dimer, coagulopathy, thrombosis

1. Introduction
The world experienced two global pandemics, severe acute
respiratory syndrome (SARS) in 2002-2003 and Middle
East Respiratory Syndrome (MERS) in 2011. The cause of
both outbreaks has been identified as a beta coronavirus
(CoV) of zoonotic origin. At the end of 2019, “Corona
Virus 2019 Disease (COVID-19)”, caused by a new type
of beta coronavirus called SARS-CoV-2, emerged as a new
pandemic in the city of Wuhan, China [1].
The SARS-CoV-2 virus causes damage to many
organs, especially the lung, and venous and arterial
thrombotic events are pervasive in patients with
COVID-19 [2,3]. These thrombotic events may be the
result of hypercoagulation caused by the inflammatory
reaction caused by SAR-CoV-2. A recent study reported
that approximately 20% of patients with COVID-19

developed venous thromboembolism (VTE), with a
cumulative incidence of VTE reaching 49% during their
hospitalization [4]. Studies have also consistently reported
a significant increase in D-dimer value. High D-dimer
levels indicate that coagulopathy plays a vital role in the
prognosis of the disease and has a remarkable impact on
mortality [5]. Evaluation of the coagulation status may be
crucial for the disease prognosis.
Thromboelastography (TEG) is a test that
evaluates clot formation and fibrinolysis in real-time,
unlike conventional coagulation tests [6,7]. Because
of this, TEG can help detect thromboembolic events
in the patient. Recent studies have reported different
hypercoagulation profiles in TEG analyzes of patients
with COVID-19 [2,3,8,9]. Chronic and infectious diseases
and their course may show genetic and ethnic differences
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between societies. Therefore, the current study aimed to
evaluate the coagulation process with TEG in patients
diagnosed with COVID-19 by real-time polymerase
chain reaction (RT-PCR) in the Turkish population. As
secondary implications, we aimed to identify risk factors
for embolic events in COVID-19 and to determine the
character of coagulation with data obtained from TEG
analysis.
2. Materials and Methods
2.1. Patients
This cross-section study was conducted by the Declaration
of Helsinki, with the approval of the local ethics committee
(2020/2779), between October 2020 and December 2020
in Necmettin Erbakan University, Meram Medical Faculty
Hospital Chest Diseases outpatient clinic. Throat swab
samples were evaluated using the RT-PCR method, and
SARS-CoV-2 positivity was detected. The study included
51 patients with positive RT-PCR tests and no previous
diagnosis of COVID-19 and no treatment for COVID-19.
The exclusion criteria were as follows: 1) need for
intensive care unit support in the last ten days; 2) taking
any anticoagulant therapy; 3) using any pharmacological
treatment that affects coagulation tests. Patients excluded
from the study population during the study period are
presented in Figure 1 as a flowchart.

2.2. Study design
Demographic data (age, gender, smoking, alcohol,
and chronic diseases) obtained during the application
process, laboratory results (white blood count cell [WBC],
lymphocyte, platelets [PLT], D-dimer, fibrinogen, ferritin,
C-reactive protein [CRP], lactate dehydrogenase [LDH]),
and hospital duration and mortality ratio were recorded
in the case study file. The lung involvement of the patients
was evaluated by computed tomography (CT) (Siemens
Samatom Drive 256, Germany). Lung CT images of patients
with COVID-19 were classified as negative, atypical,
indistinct, and typical [10]. In addition to laboratory tests,
TEG analysis was performed by taking 3 ml of a peripheral
blood sample from the brachial vein into a citrated blood
sampling tube. According to the D-dimer laboratory results,
the cases were divided into two groups as high and low.
Patients with D-Dimer level <243 ng/mL were classified as
low D-Dimer group (LDG) and patients with >243 ng/mL
level as high D-Dimer group (HDG).
2.3. Thromboelastography analysis
TEG analysis was performed with TEG 5000, version 4.2
(Haemoscope Corporation, Niles, IL, USA). 1 ml of whole
blood was taken from the citrate tube and transferred to
the kaolin tube. The blood was gently mixed for complete
contact with kaolin. Kaolin and whole blood were taken
from the mixture with a 340 µl automatic straw and placed

Patients with suspected COVID-19 (n=102)

RT-PCR Positive (n=77)

RT-PCR Negative (n=25)

Excluded
Receiving anticoagulant therapy
In need of intensive care
Receiving pharmacological treatment that
will affect coagulation tests

Not receiving anticoagulant therapy
No need for intensive care
Not receiving pharmacological treatment
to affect coagulation tests

Included (n=51)

Excluded (n=26)

D-Dimer level <243 ng/mL
Group L (n=23)

D-Dimer level >243 ng/mL
Group H (n=28)

TEG analysis

Figure 1. A flow diagram of the study design.
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in the test tube. For antagonize citrate, 20 µl of calcium
chloride was added to the test tube with an automatic straw,
and the test was analyzed, and its results were interpreted.
As a result of the analysis, reaction time (R, minute), clot
formation time (K, minute), degree (Angle), maximum
amplitude (MA, mm), and coagulation index (Cl) values
were obtained. R is the clot formation time; K is the time
taken for the amplitude of 2 mm to increase to 20 mm; The
alpha angle represents the clot formation rate, and the MA
represents the clot strength.
2.4. Statistical analysis
Statistical tests were performed using statistical software
Jamovi version 1.2.27 (The Jamovi project 2021, Sydney,
Australia). The distribution of the data was analyzed
using the Kolmogorov Smirnov test. An independent
t-test was used for the intergroup comparison of variables
with normal distribution. The data of these results were
expressed as mean ± standard error. For variables that
do not show normal distribution, the Mann-Whitney U
test was applied for intergroup comparison. These values
are also shown in the tables as median (first quarterthird quarter). The Spearman correlation test was used
to determine the correlation between D-Dimer and TEG
parameters. The statistical software MedCalc version 18.9.1
(MedCalc software bv, Ostend, Belgium) was used for the

receive operating characteristic (ROC) analysis. The area
under the curve (AUC) and the 95% confidence interval
(CI) were calculated using ROC analysis. Youden’s J statistic
determined the optimal cut-off points. A p value <0.05 was
considered statistically significant.
3. Results
The male/female ratio of 51 patients was 25/26, mean age
was 53.1±4.1 / 51.8±3.8 years, respectively (Table 1).
As a result of the comparison of TEG parameters; HDG’s
R time and K value were lower than LDG, and HDG’s Angle,
MA, and CI values were higher than LDG (respectively; p
= 0.037; p <0.001; p <0.001; p <0.001; p <0.001) (Table 2).
D-dimer and fibrinogen levels of the HDG were
remarkably higher than those of the LDG (550 ng/mL vs.
90 ng/mL, p < 0.001; 521 mg/dL vs. 269 mg/dL, p < 0.001,
respectively). The ferritin, CRP, and LDH values of HDG
were significantly higher than those of LDG, while the
lymphocyte count of HDG was significantly lower than
HDG (all p < 0.05). The hospital length of stay of HDG
was higher than that of LDG (8 days vs. one day, p <
0.001). In the follow-up of all patients after the 10th day,
no worsening was observed in the LDG. But two patients
in the HDG were taken to the intensive care unit, and one
of them died of sepsis-related multiorgan failure (Table 3).

Table 1. Age-sex distribution of the patients.
HDG
Mean+SEM (n)

LDG
Mean+SEM (n)

p value

Age (Years)

62.5 ± 2.6 (28)

40.2 ± 4.0 (23)

<0.001

Female (Years)

62.9 ± 3.2 (14)

38.9 ± 5.4 (12)

0.001

Male (Years)

62.1 ± 4.1 (14)

41.6 ± 6.3 (11)

0.009

(HDG, high D-dimer group; LDG, low D-Dimer group).
Table 2. TEG results of patients diagnosed with COVID-19
HDG (n = 28)

LDG (n = 23)

Median

Median

p value

R (min)

5.0 (4.0–6.8)

6.6 (5–7.5)

0.037

K (min)

1.7 (1.4–2.0)

4 (2.7–5.1)

<0.001

Angle (°)

65.4 (60.1–69.7)

48.5 (34.2–55.9)

<0.001

MA (mm)

67.8 (62.3–72.1)

54.4 (49.3–60.9)

<0.001

CI

1.4 (0.3–2.5)

-2.5 (-5.3–-0.9)

<0.001

Parameters

(TEG, Thromboelastography; HDG, high D-dimer group; LDG, low D-Dimer group;
R, reaction time; K, clot formation time; Angle, degree; MA, maximum amplitude;
Cl, coagulation index; min, minute; mm, millimeter). Results expressed as Median
(1. Quarter – 3. Quarter)
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As a result of the correlation analysis between D-Dimer
and TEG parameters, other TEG parameters were
statistically significant except for R (r = –0.185; p = 0.19).
K was strongly negative, angle, MA and Cl were strongly
positively correlated (respectively; r = –0.72, p < 0.001; r
= 0.64, p < 0.001; r = 0.69, p < 0.001; r = 0.65, p < 0.001).
ROC curve analysis suggested that the optimum TEG
parameters cut-off points for thrombosis risk were as
below: for K was ≤2.1 min, for R was ≤6.1 min, for Angle
was >62°, MA was 60.4 mm. All AUC, Cl, optimum cut-off
values, sensitivity, and specificity values are given in Table
4 and Figure 2.

According to the calculated cut-off values, the patients
were divided into two groups as high and low risk for
thrombosis. TEG parameters between the two groups were
statistically significant (Table 5).
4. Discussion
Coagulopathy may occur during patients with COVID-19.
The lung is the primary organ affected in this disease, but
multiorgan failure may also develop. A significant increase
in D-dimer and fibrin/fibrinogen degradation products in
COVID-19 is the first sign of the onset of the coagulopathy
event. At this stage, there are usually no abnormalities

Table 3. Laboratory results of patients diagnosed with COVID-19.
HDG (n = 28)

LDG (n = 23)

Median

Median

D-dimer (ng/mL)

550.0 (427.0–903.0)

90 (52–155)

<0.001

Fibrinogen (mg/dL)

521.0 (431.5–618.3)

269 (221–382)

<0.001

PLT (10 /uL)

252.5 (159.5–322.8)

244 (184–295)

0.895

Total Hospitalization (Day)

8 (5.25–10)

1 (1–4)

<0.001

WBC (10 /uL)

6.59 (5.3–9.7)

6.82 (5.5–8.2)

0.890

Lymphocyte (103/uL)

0.92 (0.65–1.44)

1.73 (0.9–2.4)

0.019

Ferritin (ug/L)

369.6 (180.5–842.1)

40.2 (11.7–95.9)

<0.001

CRP (mg/L)

72.39 (32.7–108.7)

5.01 (1.92–21.1)

<0.001

LDH (U/L)

328.5 (277.3–398.3)

195 (164–218)

<0.001

Parameters

3

3

p value

(HDG, high D-dimer group; LDG, low D-Dimer group; PLT, platelets; WBC, white blood cell counts; CRP, C-reactive
protein; LDH, lactate dehydrogenase). Results expressed as Median (1. Quarter – 3. Quarter)

Table 4. ROC analysis results for thrombosis risk.
Parameters

AUC

95% CI

Sensitivity

Specificity

Cut-off

p value

K (min)

0.94

0.84–0.99

82.1

95.7

≤2.1

<0.001

Ferritin (ug/L)

0.93

0.82–0.98

93

87

>125.8

<0.001

LDH (U/L)

0.91

0.80–0.97

93

87

>241

<0.001

Angle (°)

0.90

0.78–0.96

71.4

100

>62

<0.001

CI

0.90

0.79–0.97

75

96

>0.4

<0.001

MA (mm)

0.88

0.76–0.95

89

74

>60.4

<0.001

CRP (mg/L)

0.85

0.72–0.93

75

91.3

>34.8

<0.001

Lymphocyte (103/uL)

0.71

0.56–0.83

82.1

61

≤1.5

<0.006

R (min)

0.67

0.53–0.80

71.4

61

≤6.1

0.024

0.51

0.36–0.65

25

91.3

>8.8

0.960

WBC (10 /uL)
3

(AUC, area under the curve; Cl, confidence intervals; K, clot formation time; LDH, lactate dehydrogenase; Cl,
coagulation index; MA, maximum amplitude; CRP, C-reactive protein; R, reaction time; WBC, white blood cell counts).
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ROC Curve

1.0

Source of the Curve
Angle
MA
CI
Ferritin
CRP
LDH
Reference Line
WBC
R
Lymphocyte
K

Sensitivity

0.8

0.6

0.4

0.2

0.0

0.0

0.2

0.4
0.6
1 - Specificity

0.8

1.0

Figure 2. ROC curves by high D-Dimer levels.
Table 5. Comparison of patients separated according to cut-off values in terms of TEG
parameters.
Parameters

Cut-off

n

Median

R (min)

>6.1

23

7.3 (6.7–8.3)

≤6.1

28

4.8 (3.9–5.1)

>2.1

29

3.3 (2.6–4.4)

≤2.1

22

1.6 (1.3–1.8)

>62

20

49.7 (41.7–57.5)

≤62

31

67.0 (65.0–70.2)

>60.4

31

67.3 (63.0–71.5)

≤60.4

20

52.4 (48.2–58.3)

>0.4

23

1.8 (0.9–2.7)

≤0.4

28

–2.5 (from –5.2 to –1.3)

K (min)
Angle (°)
MA (mm)
CI

p value
<0.001
<0.001
<0.001
<0.001
<0.001

(TEG, Thromboelastography; R, reaction time; K, clot formation time; Angle, degree;
MA, maximum amplitude; Cl, coagulation index; min, minute; mm, millimeter). Results
expressed as Median (1. Quarter - 3. Quarter)

in prothrombin time, partial thromboplastin time, and
platelet counts [4]. Therefore, although it is recommended
to monitor D-dimer and fibrinogen levels in patients,
many centers start anticoagulant treatment as prophylactic
[11]. However, VTE may occur even under anticoagulant
therapy [5,11–13]. Therefore, evaluation of the coagulation
mechanisms of patients with COVID-19 via TEG may
help in the early diagnosis and selection of appropriate
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anticoagulant therapy. TEG analysis can show the presence
of hypercoagulation earlier than laboratory tests. Low K
and high angle and MA values indicate hypercoagulation
and vice versa show hypocoagulation [7]. According to the
results of TEG analysis in the current study, Angle and MA
values of HDG were higher than LDG, and the K value
of HDG was lower than LDG. TEG results of our study
were consistent with the presence of hypercoagulation
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without any symptoms in the patients. Correlation analysis
revealed a positive relationship between TEG results and
high D-dimer levels in our findings. According to our
findings, COVID-19 patients with high D-dimer levels
were more prone to coagulation than COVID-19 patients
with low D-dimer levels. Recently, TEG analysis in several
studies has shown that COVID-19 patients followed in the
intensive care unit are prone to hypercoagulation [8, 12–
14]. These studies were carried out in patients diagnosed
with severe COVID-19 and followed up in the intensive
care unit [3,4,7–9]. The design of our research is entirely
different from previous studies. In the current study, it
has been shown that hypercoagulability may occur in
COVID-19 patients who do not require intensive care unit
follow-up at the time of diagnosis and during the ten-day
follow-up period.
High D-dimer and fibrinogen levels in patients with
COVID-19 are closely associated with an increased
risk of developing thromboembolism, poor prognosis,
and increased mortality [11,15]. Our study showed that
patients with high D-Dimer values had a lengthy hospital
stay than patients with low D-Dimer values. In the followup of HDG patients after ten days, two patients required
intensive care support, and one of them died due to sepsis
and its complications. Previous studies have reported age,
lymphopenia, increased CRP, LDH, and ferritin levels
as predictive markers for poor prognosis in patients
with COVID-19 [16,17]. We found that HDG had lower
lymphocyte counts and higher CRP, LDH, and ferritin levels
than LDG. We also found that this change in laboratory
findings was associated with hypercoagulopathy. Detection
of the hypercoagulopathy problem before thrombosis
occurs may be vital in patients with COVID-19. Therefore,
TEG analysis can be a crucial diagnostic and followup method in these patients. We detected a high risk
of thrombosis in patients according to TEG analysis.
We obtained predictive optimum cut-off values of TEG
parameters for hypercoagulopathy by ROC analysis. Our
study may reveal that there is a risk of thrombosis even in
patients with COVID-19 who are not followed up in the
intensive care unit and that early follow-up may reduce
complications and mortality in these patients.
We found that TEG values (low K and R-value and
high MA and angle value) and increased laboratory values
(ferritin, LDH) were associated with D-dimer level. In
addition, we found that TEG values could

be a predictive

marker for thrombosis risk at high sensitivity and specificity
values. Previous studies have demonstrated that VTE can
occur even under standard thromboprophylaxis therapy in
patients with COVID-19 [4, 7]. Some studies recommend
TEG to detect the risk of coagulation in patients with
severe COVID-19 and to adjust the dose of anticoagulant
drugs for thrombosis prophylaxis and treatment [18]. A
metaanalysis showed that heparin treatment might reduce
the length of stay hospital and mortality rate in critically
ill COVID-19 patients in intensive care units [19]. Our
study revealed that heparin or other anticoagulants could
be required for thrombosis prophylaxis in patients with
COVID-19 who do not need intensive care.
Standard heparin and low molecular weight heparin are
recommended for anticoagulant selection. Heparin affects
the onset of coagulation [20,21]. As a result of literature
information and TEG analysis results, the shorter R and K
times and the large angle indicate that heparin is the right
choice in HDG. However, the high MA in HDG cases is
associated with high PLT activation and an intense clot and
indicates the prothrombotic state. Patients with COVID-19
who do not receive intensive care unit support with high
D-Dimer value, and TEG analysis results may also need to
receive heparin therapy. Our study is a pilot study. There is
a need for detailed randomized large population studies on
this subject.
5. Conclusion
Heparin treatment reduces the length of hospital stay and
mortality rate in patients with COVID-19 in the intensive
care unit. TEG analysis is beneficial in the early detection
of thrombosis risk. Our study showed that the risk of
thrombosis might increase in COVID-19 patients who are
not hospitalized in the intensive care unit. Thrombosis risk
should be investigated with TEG analysis and laboratory
tests in every patient diagnosed with COVID-19, and
treatment should be started for risky patients. However,
our study is a pilot study, and detailed further studies are
needed.
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